Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Janux Therapeutics, Inc.NASDAQ: JANX

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $37.48M rose 280.8% year over year, ahead of the +127.4% change in trailing-twelve-month operating expenses. Sequentially, it fell 9.3% from the prior quarter. Over 3 fiscal years it compounded at +30.3% a year.

Context

  • Operating expenses amounted to 1656.4% of revenue in FY2025, up 642.3 pp from a year earlier.
  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +280.8% holds above the trailing-twelve-month pace of +127.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$37.48M-9.3% QoQ
Last fiscal yearDec 2025
$165.64M+54.3% YoY
LTMMar 2026
$168.69M+127.4% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+280.8%——
1 year+54.3%——
3-year CAGR+30.3%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
165.64M USD
Year-over-year change
+54.3%
4-year CAGR
+100.1%

Operating Expenses vs competitors

How JANX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +127.4% is the 2nd highest of 10, against a peer median of +15.1%.
  • Operating expenses amounts to 780.5% of revenue for JANX, versus a peer median of 247.7%.
JANX Competitors
Operating Expenses for JANX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$740.02M USD-0.1%+14.3%54.5%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$333.75M USD+278.1%+101.5%297994.6%
IMNMImmunome, Inc.LTM Sep 2026$299.94M USD+54.6%+80.8%—
IMTXImmatics N.V.LTM Mar 2026€250M EUR+22.1%+17.2%670.3%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$240.35M USD+15.1%——
STROSutro Biopharma, Inc.LTM Mar 2026$213.41M USD-32.3%+2.0%214.2%
MGNXMacroGenics, Inc.LTM Mar 2026$173.51M USD-10.6%-12.1%110.5%
JANXJanux Therapeutics, Inc.LTM Mar 2026$168.69M USD+127.4%+30.3%780.5%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$99.95M USD-10.4%-13.9%281.2%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$74.43M USD+18.8%+19.7%—
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding JANX) —+15.1%+15.8%247.7%

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.64M8.61M8.08M10.59M10M
Cost of Revenue26.24M841K1.96M2.06M2.03M
Gross Profit(22.6M)7.77M6.13M8.53M7.97M
Gross Margin-621.4%90.2%75.8%80.5%79.7%
Research & Development26.24M53.44M54.92M68.39M125.9M
Selling, General & Admin10.33M22.26M26.14M41.05M41.77M
Operating Expenses10.33M74.86M79.11M107.38M165.64M
Depreciation & Amortization113K841K1.96M2.06M2.03M
EBITDA(32.56M)(62.22M)(56.34M)(66.93M)(111.6M)
EBITDA Margin-895.2%-722.5%-697.0%-632.2%-1116.0%
Operating Income(32.93M)(67.09M)(72.98M)(98.85M)(157.67M)
Operating Margin-905.4%-779.0%-902.9%-933.6%-1576.7%
Interest Income257K4.03M14.69M29.85M44.04M
Interest Expense00000
Other Income / Expenses257K4.03M14.69M29.85M44.04M
Income Before Tax(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Pre-Tax Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
Income Tax Expense00000
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Net Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
EPS (Basic)(0.79)(1.52)(1.32)(1.28)(1.83)
EPS (Diluted)(0.79)(1.52)(1.32)(1.28)(1.83)
Weighted Avg Shares41.24M41.47M44.02M53.75M61.97M
Weighted Avg Shares (Diluted)41.24M41.47M44.02M53.75M61.97M

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.